Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase I Study of Anetumab Ravtansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Study Type: Treatment
Phase: I
NCTID: NCT03816358
Principal Investigator:
Anup Kasi
Niraparib In Pancreatic Cancer After Previous Chemotherapy NIRA-PANC: A Phase II Trial
Study Type: Treatment
Phase: II
NCTID: NCT03553004
Principal Investigator:
Anup Kasi
A Phase II Open-Label Study of Enfortumab Vedotin in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma EPIC
Study Type: Treatment
Phase: II
NCTID: NCT05915351
Principal Investigator:
Anup Kasi
Open-label, Multicenter, Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-Claudin18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects with Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers
Study Type: Treatment
Phase: I
NCTID: NCT04404595
Principal Investigator:
Anup Kasi
A Phase 1/2 Study of M3814 Peposertib in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Study Type: Treatment
Phase: I/II
NCTID: NCT04172532
Principal Investigator:
Anup Kasi
Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma with Molecular Correlates
Phase II Randomized Trial Combining TG01 Vaccine / QS-21 Stimulon With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer TESLA
Study Type: Treatment
Phase: II
NCTID: NCT05638698
Principal Investigator:
Anup Kasi
A Phase 2 Study of Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Study Type: Treatment
Phase: II
NCTID: NCT04752696
Principal Investigator:
Anup Kasi
A Phase I/Ib Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction GEJ Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumor Have Claudin CLDN 18.2 Expression
Study Type: Treatment
Phase: I
NCTID: NCT05365581
Principal Investigator:
Anup Kasi
A Phase II, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab IMAB362 in Combination with Nab-Paclitaxel and Gemcitabine Nab-P + GEM as First Line Treatment in Subjects with Claudin 18.2 CLDN18.2 Positive, Metastatic Pancreatic Adenocarcinoma
Study Type: Treatment
Phase: II
NCTID: NCT03816163
Principal Investigator:
Anup Kasi